Operating
Stemcentrx Impairment Charge
Dollar Tree Stemcentrx Impairment Charge remained flat by 0.0% to $2.25M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 82.7%, from $13.03M to $2.25M. Over 4 years (FY 2021 to FY 2025), Stemcentrx Impairment Charge shows an upward trend with a 19.6% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryCapital Allocation
SignalLower is better
VolatilityVolatile
First reportedQ1 2021
Last reportedQ4 2025Mar 16, 2026
How to read this metric
An impairment charge signals that previous investments or acquisitions are underperforming expectations.
Detailed definition
This represents a non-cash impairment charge taken against the carrying value of specific acquired assets or goodwill wh...
Peer comparison
Company-specific; peers in M&A-heavy sectors may report similar charges following unsuccessful acquisitions.
Metric ID:
abbv_stemcentrx_impairmentHistorical Data
5 years
| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | $4.40M | $1.50M | $10.90M | $52.10M | $9.00M |
| YoY Change | — | -65.9% | +626.7% | +378.0% | -82.7% |
Range$1.50M – $52.10M
CAGR+19.6%
Avg YoY Growth+214.0%
Median YoY Growth+156.0%
Stemcentrx Impairment Charge at Other Companies
Frequently Asked Questions
- What is Dollar Tree's stemcentrx impairment charge?
- Dollar Tree (DLTR) reported stemcentrx impairment charge of $2.25M in Q4 2025.
- How has Dollar Tree's stemcentrx impairment charge changed year-over-year?
- Dollar Tree's stemcentrx impairment charge decreased by 82.7% year-over-year, from $13.03M to $2.25M.
- What is the long-term trend for Dollar Tree's stemcentrx impairment charge?
- Over 4 years (2021 to 2025), Dollar Tree's stemcentrx impairment charge has grown at a 19.6% compound annual growth rate (CAGR), from $4.40M to $9.00M.
- What does stemcentrx impairment charge mean?
- Non-cash write-down of the value of acquired assets.